Physician profile
James H Thomas
NPI 1457388985
$1,522.30
in general payments reported to CMS, 2019-2025
21 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $83.63 · 2021: $168 · 2022: $240 · 2023: $168 · 2024: $195 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622 · Consulting Fee: $175 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.20 |
| Consulting Fee | $175.00 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $237.07 | 2019-2025 | Prolia, Tavneos, Otezla |
| Astrazeneca Pharmaceuticals LP | $235.52 | 2019-2025 | Breztri, Airsupra, Evusheld |
| Janssen Pharmaceuticals, INC | $124.39 | 2019-2022 | |
| Astellas Pharma US INC | $108.22 | 2019-2020 | |
| Lundbeck LLC | $106.40 | 2022-2023 | Vyepti |
| Cvrx, INC. | $98.74 | 2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $80.16 | 2019-2023 | Verquvo, Belsomra, Lagevrio |
| Pfizer INC. | $78.92 | 2019-2025 | |
| Glaxosmithkline, LLC. | $78.61 | 2022-2023 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $78.13 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $73.22 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $45.14 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $41.95 | 2021-2022 | |
| Exact Sciences Corporation | $27.98 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $24.31 | 2023 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.08 | 2022 | |
| Abbvie INC. | $16.55 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.40 | 2023 | Quviviq |
| Almatica Pharma LLC | $14.61 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$475,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.